Oxford and GSK launch £50m programme to advance cancer research
Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
Read moreLaunch of 'To Immunity and Beyond' podcast series
Read morePancreatic cancer immune map provides clues for precision treatment targeting
Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
Read moreLatest News
Upcoming Talks
From the Laboratory to the Clinic 2026: Complex pathogenesis of disease
Tuesday, 1 September 2026 to Friday, 4 September 2026, 9am - 6pm
Epigenomic Variation Reveals the Hijacking of Transposable Elements in Cancer
Friday, 4 September 2026, 11am to 12pm
CSM's Randomised Controlled Trials Course: A Guide to Design, Conduct, Analysis, Interpretation and Reporting of RCTs
Monday, 7 September 2026 to Friday, 11 September 2026, 9am - 2pm
Molecular basis of T cell antigen recognition and immune escape in viral infections: lessons from SARS-CoV-2 infection
Monday, 7 September 2026, 3pm to 4pm